SEC Form 10-Q Summary
Filing identity: The provided filing is for DanDrit Biotech USA, Inc., not Lunai Bioworks Inc. It covers the three months ended September 30, 2016, the first quarter of fiscal 2017 following the company’s June 30 fiscal year-end. The financial statements are unaudited.
Business Context and Reporting Period
DanDrit is a development-stage biopharmaceutical company focused on dendritic-cell cancer immunotherapies, principally its MelCancerVac product candidate for colorectal cancer. The product had only limited compassionate-use availability in Singapore and was not approved for general sale elsewhere. The company’s operations are conducted primarily through its Danish subsidiary, DanDrit Biotech A/S.
Key Financial Metrics
| Metric | Three months ended September 30, 2016 | Comparable 2015 period |
|---|---|---|
| Revenue | $0 | $0 |
| Operating expenses | $852,291 | $341,395 |
| Loss from operations | $(852,291) | $(341,395) |
| Other income/(expense), net | $18,603 | $(32,820) |
| Net loss | $(793,181) | $(350,302) |
| Basic and diluted loss per share | $(0.08) | $(0.04) |
| Net cash used in operating activities | $(326,496) | $(416,036) |
| Net cash provided by financing activities | $360,900 | $0 |
| Cash at period end | $31,675 | $1,048,120 |
Gross margin was not meaningful because the company reported no revenue or cost of goods sold. The company reported a comprehensive loss of $818,769, including a $25,588 foreign-currency translation loss.
At September 30, 2016, total assets were $944,684, including $31,675 of cash and $746,452 of other receivables. Total liabilities were $1,742,669, compared with $1,508,229 at June 30, 2016. Stockholders’ deficit was $(797,985), compared with $(637,398) at June 30, 2016. Working capital was negative $625,497.
Debt included $103,538 of related-party notes payable, $102,941 of related-party convertible notes, and $229,669 of other convertible notes, net of discounts. The convertible notes had aggregate face amounts of $360,900, were convertible at $2.00 per share, and generally matured December 31, 2017.
Material Changes Versus the Prior Comparable Period
- Operating expenses increased by $510,896, or approximately 150%, primarily because the company recognized $626,487 of non-cash stock-option compensation.
- Net loss increased by $442,879, or approximately 126%, to $793,181.
- Research and development expense declined 83% to $17,104 from $101,759; management attributed the expense to work related to the Phase III MelCancerVac clinical trial.
- General and administrative expense was substantially unchanged at $204,951 versus $204,851.
- Consulting expense declined to zero from $30,848.
- Operating cash burn improved to $326,496 from $416,036, but cash remained very limited.
- The company raised $360,900 through notes payable during the quarter, including $138,070 from related-party notes and $222,830 from other notes.
- The company granted 900,000 fully vested stock options to employees, officers, and directors at a $2.00 exercise price. The options expire December 31, 2019.
Guidance, Outlook, Risks, and Unusual Items
Management provided no quantified revenue or earnings guidance. Its stated plan was to continue seeking capital and pursue revenue opportunities associated with MelCancerVac. Management stated that the company may require additional debt or equity financing to fund operations and strategic opportunities.
The filing contains a substantial doubt going-concern disclosure. The company has incurred significant losses, has not established profitable operations, and has short-term obligations exceeding anticipated cash. Management planned to seek at least $15 million through a private placement and to close the proposed acquisition of OncoSynergy, Inc.; there was no assurance that either the financing or profitable operations would be achieved.
On September 15, 2016, the company filed a Form D seeking up to $16.5 million of additional equity capital. The proposed OncoSynergy acquisition was expected to result in OncoSynergy shareholders owning approximately 33% to 40% of the combined company on a fully diluted basis. Subsequent to quarter-end, the closing date was amended to December 31, 2016, and certain closing conditions were waived.
The company reported material weaknesses in disclosure controls and procedures, citing inadequate accounting resources, insufficient segregation of duties, and limited U.S. GAAP and SEC reporting expertise. Consultants were engaged to review and compile financial information, but management expected the deficiencies to continue until sufficient capital was available to hire additional personnel.
Additional risks include regulatory approval and clinical-trial uncertainty, limited product commercialization, potential product-liability exposure, dependence on future financing, foreign-currency effects, related-party financing and obligations, dilution from convertible notes and options, and potential impairment of patents or other long-lived assets.
Most Important Facts for Investors to Verify
- Confirm the issuer identity: the supplied filing is DanDrit Biotech USA, Inc., not Lunai Bioworks Inc.
- Verify whether the company obtained the planned private-placement financing and whether the OncoSynergy acquisition closed after November 14, 2016.
- Assess liquidity against the $31,675 cash balance, negative $625,497 working capital, and substantial debt and payables.
- Review the going-concern disclosure and the company’s ability to fund operations without additional financing.
- Evaluate the clinical, regulatory, and commercialization status of MelCancerVac, including the Phase III trial.
- Consider dilution from $360,900 of convertible notes and 900,000 outstanding stock options.
- Review the reported material weaknesses in internal controls and any subsequent remediation.